Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GBA haploinsufficiency accelerates alpha-synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson’s disease

26 Jan 2019

Abstract excerpt

Parkinson's disease (PD) is characterized by dopaminergic (DA) cell loss and the accumulation of pathological alpha synuclein (asyn), but its precise pathomechanism remains unclear, and no appropriate animal model has yet been established. Recent studies have shown that a heterozygous mutation of glucocerebrosidase (gba) is one of the most important genetic risk factors in PD. To create mouse model for PD, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lysosomal Storage Disorders Research
Share to Neurological diseases and metabolism
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30689867
DOI: 10.1093/hmg/ddz030

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GBA haploinsufficiency accelerates alpha-synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson’s diseasePMID 30689867Read ↗

Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.Semantic proximity Read ↗

Neuronopathic GBA1 L444P mutation accelerates Glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusionsSemantic proximity Read ↗

GBA Variants and Parkinson Disease: Mechanisms and Treatments.Semantic proximity Read ↗

Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.Semantic proximity Read ↗

The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson’s diseaseSemantic proximity Read ↗

Glucocerebrosidase Mutations in Parkinson Disease.Semantic proximity Read ↗

Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways.Semantic proximity Read ↗

GBA mutation exacerbates α-synuclein pathology with involvement of ROS and p38 MAPK signaling in Parkinson's disease.Semantic proximity Read ↗

The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models.Semantic proximity Read ↗

Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions.Semantic proximity Read ↗

Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.Semantic proximity Read ↗

Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.